Journal of Autoimmunity

2006

DOI: 10.1016/j.jaut.2006.09.007

|View full text |Cite

|

Sign up to set email alerts

|

Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of β2-GPI

¹

,

Carlos Alberto von Mühlen

²

,

Henrique Luiz Staub

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction2

Reactivity Towards Domains Iv/v Of β 2 Glycoprotein I1

Discussion1

Citation Types

Supporting

3

Mentioning

40

Contrasting

0

Unclassified

2

Year Published

2008

2008

2017

2017

Publication Types

Select...

Article7

Book3

Relationship

Self Cite3

Independent7

Authors

Journals

Cited by 68 publications

(45 citation statements)

References 16 publications

Supporting

3

Mentioning

40

Contrasting

0

Unclassified

2

Order By: Relevance

“…It can be derived that the interaction between DIV and DV may be essential to expose the suitable structure for antibody binding. Conversely, only constructs containing DI were able to inhibit binding of both IgG and IgA antibodies isolated from APS patients [24]. Similar findings were reported in 2011 by Andreoli et al, who examined by ELISA kits the specificities of anti-β 2 GPI antibodies in one-year old healthy children born to mothers with systemic autoimmune diseases and in children with atopic dermatitis.…”

Section: Reactivity Towards Domains Iv/v Of β 2 Glycoprotein Isupporting

confidence: 85%

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity. aPL are detected in 20 to 50% of patients with systemic lupus erythematosus (SLE), representing a poor prognostic factor. Indeed, thrombotic events heralds high morbidity and mortality, being regarded as the strongest predictors of death in the first five years after SLE onset. It would be thus very important to identify a reliable laboratory tool such as anti-domain antibodies to better risk-stratify lupus patients according to the aPL profile, in order to tailor treatment strategies. Domain I (DI) of β 2 GPI has lately been identified as the main epitope targeted by antibodies reacting against β 2 GPI isolated from APS patients, well correlating with thrombotic as well as obstetric manifestations. Interestingly, anti-DI antibodies have been shown to well correlate with lupus anticoagulant and to predict the clinical manifestations of the syndrome, thrombotic events as well as pregnancy complications. Further, anti-DI antibodies allow to identify patients at highest clinical risk, presenting a good specificity for APS. On the other hand, anti-β 2 GPI antibodies from aPL asymptomatic carriers or subjects with infectious diseases preferentially display reactivity towards DIV or DV of the molecule.Few studies have to date evaluated the domain profile of anti-β 2 GPI antibodies in subjects with SLE, even though it would be very relevant from a clinical point of view to understand whether among patients with SLE the domain specificities of anti-β 2 GPI antibodies display a clinical meaning comparable to the one they exert in APS. It is therefore rather appropriate to review the available evidence about anti-domain specificities with a particular focus on SLE.

“…It can be derived that the interaction between DIV and DV may be essential to expose the suitable structure for antibody binding. Conversely, only constructs containing DI were able to inhibit binding of both IgG and IgA antibodies isolated from APS patients [24]. Similar findings were reported in 2011 by Andreoli et al, who examined by ELISA kits the specificities of anti-β 2 GPI antibodies in one-year old healthy children born to mothers with systemic autoimmune diseases and in children with atopic dermatitis.…”

Section: Reactivity Towards Domains Iv/v Of β 2 Glycoprotein Isupporting

confidence: 85%

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity. aPL are detected in 20 to 50% of patients with systemic lupus erythematosus (SLE), representing a poor prognostic factor. Indeed, thrombotic events heralds high morbidity and mortality, being regarded as the strongest predictors of death in the first five years after SLE onset. It would be thus very important to identify a reliable laboratory tool such as anti-domain antibodies to better risk-stratify lupus patients according to the aPL profile, in order to tailor treatment strategies. Domain I (DI) of β 2 GPI has lately been identified as the main epitope targeted by antibodies reacting against β 2 GPI isolated from APS patients, well correlating with thrombotic as well as obstetric manifestations. Interestingly, anti-DI antibodies have been shown to well correlate with lupus anticoagulant and to predict the clinical manifestations of the syndrome, thrombotic events as well as pregnancy complications. Further, anti-DI antibodies allow to identify patients at highest clinical risk, presenting a good specificity for APS. On the other hand, anti-β 2 GPI antibodies from aPL asymptomatic carriers or subjects with infectious diseases preferentially display reactivity towards DIV or DV of the molecule.Few studies have to date evaluated the domain profile of anti-β 2 GPI antibodies in subjects with SLE, even though it would be very relevant from a clinical point of view to understand whether among patients with SLE the domain specificities of anti-β 2 GPI antibodies display a clinical meaning comparable to the one they exert in APS. It is therefore rather appropriate to review the available evidence about anti-domain specificities with a particular focus on SLE.

“…Anti-β2-gpI antibodies from APS patients target the domain 1 of the molecule 30 . In recent years, it has been shown that IgA antibodies from patients with atherosclerosis recognize specifically domain 4 of β2-gpI 31 . Thus, a distinct subgroup of anti-β2-gpI antibodies in patients with atherosclerotic disease could be postulated.…”

Section: Discussionmentioning

confidence: 99%

Auto-anticorpos anti-β2-glicoproteína I e síndrome metabólica

et al. 2011

Arq. Bras. Cardiol.

Self Cite

View full text Add to dashboard Cite

Background: The metabolic syndrome (MetS) is a proatherogenic entity. Autoantibodies to phospholipid cofactors such as beta2-glycoprotein I (beta2-gpI) can influence atheroma appearance. Previous studies confirmed an association of IgA anti-beta2-gpI antibodies with cerebral ischemia, myocardial infarction, peripheral artery disease and carotid disease.

“…Moreover, while no significant differences of IgG aCL levels have been found between the Kawasaki disease and febrile patients, IgM and IgA aCL were significantly higher in patients with acute Kawasaki disease compared to febrile children [11]. In addition, samples from atherosclerosis patients with low IgA aCL level presented high levels of IgA anti-beta 2-GPI [12]. There is also evidence in the origins and specificities of IgG, IgM, and IgA aCL [13].…”

Section: Introductionmentioning

confidence: 88%

IgA Anticardiolipin in Patients with Gastroenteric Tumor

³

et al. 2009

Scholarly Research Exchange

View full text Add to dashboard Cite

Recently the presence of antiphospholipid antibodies in patients with cancer has been demonstrated, suggesting an involvement of autoimmune response in neoplastic conditions. The presence of antiphospholipid antibodies in tumor disease is highly correlated with the risk of developing thrombotic complications, which represents a significant cause of morbidity and mortality in cancer patients. Interestingly, it has been highlighted that high levels of IgM and IgG anticardiolipin antibodies are more often produced in patients with gastroenteric tumor than in patients with either ovarian or breast tumor. Thus far, there are no data looking into the role or measurements of IgA in patients with solid cancer. Our preliminary results, in this study, demonstrate that testing only for IgG and IgM anticardiolipin antibodies may increase the incidence of false positive because 44% who were IgA positive and IgG and IgM negative had high titres of CA19.9 and CEA. We suggest that taking into account the role of IgA could substantially improve the detection of antiphospholipids antibodies in subjects with solid cancer, and this detection may allow us for better prevention and management of thrombotic complications in these patients.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2025 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.